DelveInsight’s, “Muscle Invasive Bladder Cancer Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Muscle Invasive Bladder Cancer pipeline landscape. It covers the Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Muscle Invasive Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Muscle Invasive Bladder Cancer Pipeline? @ https://www.delveinsight.com/sample-request/muscle-invasive-bladder-cancer-pipeline-insight

Key Takeaways from the Muscle Invasive Bladder Cancer Pipeline Report

• On June 2026- Protara Therapeutics conducted a phase 3 clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older.
• On June 26, 2026- Merck Sharp & Dohme LLC initiated a phase 3 study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy [gemcitabine plus cisplatin] and RC + PLND) for participants with MIBC who are cisplatin-eligible. The primary hypothesis is perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS) compared with neoadjuvant gemcitabine + cisplatin and RC + PLND (Arm B).
• On June 23, 2026- Janssen Research & Development LLC conducted a phase 2 study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone. Bladder cancer is the tenth most common malignancy worldwide. Approximately 25 percent (%) of all new bladder cancer participants present with muscle invasive bladder cancer (MIBC) at the time of diagnosis, and roughly 50% will ultimately develop distant metastases.
• On June 22, 2026- enGene, Inc. conducted a phase 1/2 study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with: NMIBC with CIS for whom BCG therapy is unresponsive, and other high risk patients with NMIBC.
• On June 18, 2026- Canadian Cancer Trials Group initiated a phase II study is looking at whether a type of immunotherapy drug called durvalumab can be safely administered after initial treatment received by a patient. Durvalumab has been tested in many different types of cancers. Durvalumab works by allowing the immune system to detect cancer and reactivate the immune response. This may help to slow down the growth of cancer or may cause cancer cells to die. It is unclear if the addition of durvalumab is beneficial in patients with bladder cancer who have completed surgery, radiotherapy and chemotherapy.
• On June 17, 2026- Ferring Pharmaceuticals announced a phase 3b study trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC).
• DelveInsight’s Muscle Invasive Bladder Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Muscle Invasive Bladder Cancer treatment.
• The leading Muscle Invasive Bladder Cancer Companies such as Aura Biosciences, Janssen Research & Development LLC, Asieris Pharmaceuticals, RemeGen Co., Ltd. and others.
• Promising Muscle Invasive Bladder Cancer Therapies such as Pembrolizumab, Gemcitabine, TAR-210, Mitomycin C, RC48-ADC, JS001, Oncofid-P-B, Cisplatin, Tremelimumab and others.

Want to know which companies are leading innovation in Muscle Invasive Bladder Cancer? @ Muscle Invasive Bladder Cancer Clinical Trials Assessment

The Muscle Invasive Bladder Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Muscle Invasive Bladder Cancer Pipeline Report also highlights the unmet needs with respect to the development of Muscle Invasive Bladder Cancer.

Muscle Invasive Bladder Cancer Overview

Muscle invasive bladder cancer (MIBC) is a type of bladder cancer that has grown into the muscle layer of the bladder wall. This is a more aggressive form of bladder cancer compared to non-muscle invasive types and requires more intensive treatment. MIBC accounts for about 25% of all bladder cancer cases and is associated with a higher risk of metastasis and lower survival rates. The main risk factors include smoking, exposure to industrial chemicals, chronic bladder inflammation, and certain genetic predispositions.

Muscle Invasive Bladder Cancer Emerging Drugs Profile

• TAR-200 : Janssen Research & Development, LLC

TAR-200 is a novel investigational small molecule targeted releasing system enabling controlled release of gemcitabine into the bladder, sustaining local drug exposure for weeks at a time. The safety and efficacy of TAR-200 are being evaluated in Phase II and Phase III studies in patients with muscle-invasive bladder cancer in SunRISe-2 and SunRISe-4. Currently, the drug is in Phase III stage of its development for the treatment of Muscle Invasive Bladder Cancer.

• AU-011: Aura Biosciences

AU-011 is a first-in-class targeted therapy in development for the muscle Invasive Bladder Cancer and noninvasive muscle bladder cancer. The drug candidate is being developed by Aura Biosciences. The drug is death stimulants and photosensitisers and also works as reactive oxygen species stimulants thus having mechanism of action. Currently, the drug is in Phase I stage of its development for the treatment of Muscle Invasive Bladder Cancer.

The Muscle Invasive Bladder Cancer Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Muscle Invasive Bladder Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Muscle Invasive Bladder Cancer Treatment.
• Muscle Invasive Bladder Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Muscle Invasive Bladder Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Muscle Invasive Bladder Cancer market.

If you’re tracking ongoing Muscle Invasive Bladder Cancer clinical trials, this press release is a must-read @ Muscle Invasive Bladder Cancer Treatment Drugs

Muscle Invasive Bladder Cancer Companies

Aura Biosciences, Janssen Research & Development LLC, Asieris Pharmaceuticals, RemeGen Co., Ltd. and others.

Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Muscle Invasive Bladder Cancer Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Muscle Invasive Bladder Cancer Pipeline Report covers it all @ Muscle Invasive Bladder Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Muscle Invasive Bladder Cancer Pipeline Report

• Coverage- Global
• Muscle Invasive Bladder Cancer Companies- Aura Biosciences, Janssen Research & Development LLC, Asieris Pharmaceuticals, RemeGen Co., Ltd. and others.
• Muscle Invasive Bladder Cancer Therapies- Pembrolizumab, Gemcitabine, TAR-210, Mitomycin C, RC48-ADC, JS001, Oncofid-P-B, Cisplatin, Tremelimumab and others.
• Muscle Invasive Bladder Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Muscle Invasive Bladder Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Muscle Invasive Bladder Cancer treatment landscape in this detailed analysis @ Muscle Invasive Bladder Cancer Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Muscle Invasive Bladder cancer: Overview
4. Comparative Analysis
5. Therapeutic Assessment
6. Muscle Invasive Bladder cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. TAR-200 : Janssen Research & Development, LLC
9. Mid Stage Products (Phase II)
10. Early Stage Products (Phase I)
11. AU-011: Aura Biosciences
12. Research and Development
13. Product Development Activities
14. Preclinical and Discovery Stage Products
15. Drug Name: Company Name
16. Research and Development
17. Product Development Activities
18. Inactive Products
19. Muscle Invasive Bladder cancer Key Companies
20. Muscle Invasive Bladder cancer Key Products
21. Muscle Invasive Bladder cancer- Unmet Needs
22. Muscle Invasive Bladder cancer- Market Drivers and Barriers
23. Muscle Invasive Bladder cancer- Future Perspectives and Conclusion
24. Muscle Invasive Bladder cancer Analyst Views
25. Muscle Invasive Bladder cancer Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/muscle-invasive-bladder-cancer-pipeline-insight